In the last few years, there has been an increase in research around using psychedelic drugs, like LSD and magic mushrooms, as treatments for mental health conditions. And recently, two Canadian companies working in the sphere have gotten a special designation from a big U.S. regulator that could fast-track the development and review of their drugs.
Sean Silcoff is a journalist with The Globe’s Report on Business. He has been looking at recent developments in these companies and how that fits into the bigger picture of investor excitement around these drugs.
Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com
The Odysseus lunar landing and a new space race
The landmark decision on white nationalist terrorism
On the ground in Kharkiv, two years into the Russian invasion
Is Trudeau leading the Liberals to an election day shellacking?
Investigating Canada’s dependence on for-profit nursing
The Federal Housing Advocate on the national encampment crisis
The Alberta credit union betting on gold over government
Inside the power struggle over Rogers’ telecom empire
Palestinians fleeing Gaza face hurdles coming to Canada
The rising costs of pet ownership
China sets its sights on the Arctic
Why the ‘last mile’ of inflation is the hardest
A year of drug decriminalization in B.C.
Fact-checking Alberta’s new gender-affirming care policies
The U.S. states vying for cheaper drugs from Canada
TD Bank’s anti-money-laundering troubles
Hells Angels, an Iranian drug lord and an alleged murder plot
The five pro hockey players charged with sexual assault
Debate around Israel-Hamas war collides with Canadian theatre
On the new frontlines of Myanmar’s civil war
Create your
podcast in
minutes
It is Free
As It Happens
The Daily
Morning Wire
Up First
Dobré ráno | Denný podcast denníka SME